Blog‎ > ‎

Even more crosslinking news

posted Mar 13, 2012, 6:05 PM by Jen Weigel
From the official press release from Avedro:

"Avedro, Inc. announced today that the Company submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for its VibeX(TM) (riboflavin ophthalmic solution) /KXL(TM) System for the treatment of keratoconus and corneal ectasia following refractive surgery."

This company is hot!  They have been making so much progress overseas and in Canada recently, but this is the first official happening that I have seen in the US so far.  Keep a look out for crosslinking to become a sweet option for your patients who really need help in obtaining better eye health.  You can read more about crosslinking progress here.  - jw
Comments